Tipapkinogene sovacivec is under clinical development by Transgene and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tipapkinogene sovacivec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tipapkinogene sovacivec overview
Tipapkinogene sovacivec (TG-4001, RG3484) is under development for the treatment of cervical intraepithelial neoplasia associated with high risk HPV infection and human papilloma virus 16-positive metastatic or refractory/recurrent cancers including cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer and head and neck squamous cell carcinoma including oropharyngeal SCCHN. The vaccine candidate is administered subcutaneously in the form of suspension. The vaccine candidate is a modified virus Ankara nonpropagating, attenuated vaccinia virus backbone into which DNA for HPV 16 associated antigens (E6 and E7) and interleukin 2 is engineered. The drug candidate is based on Co-X-Gene Technology and Invir.IO platform technology.
Transgene overview
Transgene, a subsidiary of Institut Merieux SA, is a biotechnology company that discovers and develops targeted immunotherapies for the treatment of cancer. The company pipeline products include TG4050 and TG4001 for the indications of Anogenital Human papillomavirus (HPV)-positive cancer, Head and Neck Cancer (Adjuvant) and other indications. Transgene‘s other pipelines include TG6002, BT-001 and TG6050 for solid tumors and lung cancers. The company utilizes technology platforms such as myvac and invir.IO. The company myvac is designed to stimulate and educate the patient’s immune system to recognize and destroy tumors using their cancer-specific genetic mutations. Transgene is headquartered in Illkirch-Graffenstaden, Alsace, France.
For a complete picture of Tipapkinogene sovacivec’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
